Oslif Breezhaler (Indacaterol)

Indacaterol, the active ingredient in Oslif Breezhaler, is a long‑acting beta2‑adrenergic agonist presented as an inhalation powder for oral inhalation use. It provides maintenance bronchodilation for adults with chronic obstructive pulmonary disease (COPD). GNH USA supplies Oslif Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oslif Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Indacaterol is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic respiratory disease.

- Chronic obstructive pulmonary disease (COPD): provides once‑daily maintenance bronchodilation and reduces exacerbation risk. - Exercise‑induced bronchoconstriction: improves tolerance to physical activity in patients with underlying airway hyper‑responsiveness. - Asthma (as add‑on therapy): offers additional bronchodilation when standard inhaled corticosteroids and long‑acting agents are insufficient.

Indacaterol may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Cough - Throat irritation - Nasal congestion - Headache - Dry mouth - Upper respiratory tract infection

Serious or Rare Side Effects: - Paradoxical bronchospasm - Cardiovascular events such as tachycardia or palpitations - Severe hypersensitivity reactions including anaphylaxis - Pneumonia - Significant drop in blood pressure - Acute worsening of COPD symptoms

When using Oslif Breezhaler, patients and healthcare providers should consider several safety measures.

- Assess respiratory status: evaluate baseline lung function before initiating therapy. - Monitor cardiovascular health: watch for tachycardia, arrhythmias, or hypertension. - Review concomitant medications: avoid duplicate β2‑agonist therapy. - Caution in severe COPD: patients with very low FEV1 may require additional monitoring. - Educate on proper inhaler technique: ensure correct device handling to achieve intended dose. - Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Indacaterol can interact with other medicines that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid): - Non‑selective β‑blockers: may blunt bronchodilator response and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of tachycardia and hypertensive episodes.

Moderate Interactions (Monitor Closely): - Other long‑acting β2‑agonists or short‑acting bronchodilators: may increase risk of cardiovascular side effects. - Diuretics: potential additive effect on heart rate and blood pressure. - Theophylline: may enhance β2‑agonist effects, requiring careful observation.